CancerDrs

Melanoma clinical trials in Alabama

10 actively recruiting melanoma trials at 3 sites across Alabama.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Industry

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unr…

Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT05727904
Sites in Alabama:
  • University of Alabama at Birmingham: The Kirklin Clinic — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Alabama:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Thomas Hospital — Fairhope, Alabama
  • Mobile Infirmary Medical Center — Mobile, Alabama
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Alabama:
  • Children's Hospital of Alabama — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma. DOC1021 is a dendritic cell immunotherapy derived from a patient's own blood cells and loaded…

Sponsor: Diakonos Oncology Corporation
NCT ID: NCT07288112
Sites in Alabama:
  • The University of Alabama at Birmingham — Birmingham, Alabama
View on ClinicalTrials.gov →
Recruiting Network

Project: Every Child for Younger Patients With Cancer

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…

Sponsor: Children's Oncology Group
NCT ID: NCT02402244
Sites in Alabama:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • USA Health Strada Patient Care Center — Mobile, Alabama
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1…

Sponsor: Melanoma and Skin Cancer Trials Limited
NCT ID: NCT03860883
Sites in Alabama:
  • University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Alabama:
  • Massive Bio SYNERGY-AI site — Birmingham, Alabama
  • Massive Bio SYNERGY-AI site — Mobile, Alabama
View on ClinicalTrials.gov →
Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Alabama:
  • Research Site — Birmingham, Alabama
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.

Sponsor: Stanford University
NCT ID: NCT05297734
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • University of South Alabama — Mobile, Alabama
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07